These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8423889)

  • 1. Increase of Parkinson disability after fluoxetine medication.
    Steur EN
    Neurology; 1993 Jan; 43(1):211-3. PubMed ID: 8423889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does fluoxetine exacerbate Parkinson's disease?
    Caley CF; Friedman JH
    J Clin Psychiatry; 1992 Aug; 53(8):278-82. PubMed ID: 1500404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
    Montastruc JL; Fabre N; Blin O; Senard JM; Rascol O; Rascol A
    Mov Disord; 1995 May; 10(3):355-7. PubMed ID: 7651460
    [No Abstract]   [Full Text] [Related]  

  • 4. [Parkinsonism following addition of fluoxetine to the treatment with neuroleptics or carbamazepine].
    Touw DJ; Gernaat HB; van der Woude J
    Ned Tijdschr Geneeskd; 1992 Feb; 136(7):332-4. PubMed ID: 1347157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exacerbation of parkinsonism caused by fluoxetine].
    Gatto EM; Fernández Pardal M; Micheli F
    Medicina (B Aires); 1994; 54(2):182. PubMed ID: 7997141
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoxetine and parkinsonism in patients taking carbamazepine.
    Gernaat HB; Van de Woude J; Touw DJ
    Am J Psychiatry; 1991 Nov; 148(11):1604-5. PubMed ID: 1928486
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinsonism associated with fluoxetine and cimetidine: a case report.
    Leo RJ; Lichter DG; Hershey LA
    J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):231-3. PubMed ID: 8561837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fluoxetine and extrapyramidal symptoms. Two case reports].
    Daric C; Dollfus S; Mihout B; Omnient Y; Petit M
    Encephale; 1993; 19(1):61-2. PubMed ID: 8275894
    [No Abstract]   [Full Text] [Related]  

  • 9. [Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
    Keppel Hesselink JM
    Ned Tijdschr Geneeskd; 1992 Apr; 136(15):754-5. PubMed ID: 1348574
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluoxetine and extrapyramidal side effects.
    Am J Psychiatry; 1989 Oct; 146(10):1352-3. PubMed ID: 2604792
    [No Abstract]   [Full Text] [Related]  

  • 11. [Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
    Jansen EN; Kölling P
    Ned Tijdschr Geneeskd; 1992 Apr; 136(15):755-6. PubMed ID: 1560870
    [No Abstract]   [Full Text] [Related]  

  • 12. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
    Morley JF; Pawlowski SM; Kesari A; Maina I; Pantelyat A; Duda JE
    Parkinsonism Relat Disord; 2014 Jul; 20(7):738-42. PubMed ID: 24742370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
    Berghauzen-Maciejewska K; Kuter K; Kolasiewicz W; Głowacka U; Dziubina A; Ossowska K; Wardas J
    Behav Brain Res; 2014 Sep; 271():343-53. PubMed ID: 24956561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline, fluoxetine, and depression in Parkinson's disease.
    Garcia-Monco JC; Padierna A; Gomez Beldarrain M
    Mov Disord; 1995 May; 10(3):352. PubMed ID: 7651457
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinically silent idiopathic Parkinson's disease unmasked by valproate use: a brief report.
    Athauda D; Batley R; Ellis C
    Aging Clin Exp Res; 2015 Jun; 27(3):387-90. PubMed ID: 25365950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Environmental determinants of Parkinson's disease.
    Wright JM; Keller-Byrne J
    Arch Environ Occup Health; 2005; 60(1):32-8. PubMed ID: 16961006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
    Huang HC; Tsai CH; Muo CH; Lin KH; Lu MK; Sung FC; Kao CH
    J Clin Psychiatry; 2015 Jan; 76(1):e104-10. PubMed ID: 25650675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of idiopathic Parkinson's disease by naproxen.
    Shaunak S; Brown P; Morgan-Hughes JA
    BMJ; 1995 Aug; 311(7002):422. PubMed ID: 7640588
    [No Abstract]   [Full Text] [Related]  

  • 20. Is it Parkinson's disease?
    Hely M
    Aust Fam Physician; 1992 Oct; 21(10):1411-6. PubMed ID: 1444967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.